Subtitle
Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial.
Subtitle
Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial.
Proto therapy Time
July and August 2023
Executive summary
This study by the Heidelberg group reported clinical outcomes of 25 patients with uterine cervical or endometrial cancer treated with postoperative PBT. Proton radiation was delivered to a total dose of 45 to 50.4 Gy (RBE) in 5 to 6 × 1.8 Gy (RBE) fractions weekly. No patient developed gastrointestinal or genitourinary toxicity ≥grade 3, and the treatment tolerability rate was 100%. With a median follow-up time of 25.1 months, 7 patients had progressive disease. The conclusion of this study is that postoperative IMPT is a safe treatment option for cervical and endometrial cancer patients, with only low-grade acute and late toxicities.
Top cancer treatments
Related contents
Proton Therapy Publication
May 2024
Bone Marrow Sparing by Intensity Modulated Proton Beam Therapy in Postoperative Irradiation of Gynecologic Malignancies.
Proton Therapy Publication
May 2023
Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.
Proton Therapy Publication
November 2022
Outcomes of Proton Beam Therapy Compared With Intensity-Modulated Radiation Therapy for Uterine Cancer.
Proton Therapy Publication
January 2023
Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial.
Proton Therapy Publication
May 2023
Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.